This course is available as a stand-alone purchase, part of the Pediatric Neuromuscular Course Bundle, or the 2024 Annual Meeting Video Collection.

Review the current FDA approved therapies for DMD and discuss the benefits and limitations of each; recognize the role of each in the general landscape of treatment; and create a framework for thinking through how to apply these therapies to real world patients.

FORMAT: Recorded session from the 2024 Annual Meeting.

OBJECTIVES:
1) Learn the current FDA approved therapies for DMD; 2) highlight the benefits and limitations of available therapies; 3) learn how to apply these therapies to patients in your practice.

ACCREDITATION STATEMENT
The AANEM is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION :
The AANEM designates this enduring material for a maximum of 1.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

All relevant financial relationships have been mitigated.

Speakers:

Nancy Kuntz, MD

• Astellas, argenx, Catalyst, Entrada, Genentech, Novartis, Sarepta- Advisory Board
• Sarepta- Exchange Expert On-Demand Program
• Sarepta Genentech, Sarepta, Solid Biosciences- Speaker
• Astellas, argenx, Biogen, Catalyst, Genentech, Novartis, Sarepta- research funding

Craig Zaidman, MD

• Biogen- Consultant
• Sarepta- Research support 
• Novartis- Speaker fees